CNTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Centessa Pharmaceuticals (CNTA) is not a good buy for a beginner, long-term investor at this time. The stock is currently under an acquisition agreement by Eli Lilly for $38 per share in cash, with an additional contingent value right (CVR) of up to $9 per share. This caps the upside potential, and the stock is trading near the acquisition price. Furthermore, insider selling has significantly increased, and the company's financial performance is weak, with declining net income and EPS. While hedge funds are buying, the acquisition limits the potential for significant long-term growth.
The technical indicators show a bullish trend with MACD above 0, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and RSI at 77.045 in the neutral zone. However, the stock is trading near its acquisition price of $38, limiting further upside.
The acquisition by Eli Lilly for $38 per share plus a CVR worth up to $9 per share reflects confidence in Centessa's drug development potential, particularly in sleep disorder treatments.
Significant insider selling (up 833.42% in the last month), weak financial performance with declining net income and EPS, and potential shareholder rights investigations related to the acquisition.
In Q4 2025, revenue remained at $0, net income dropped by 40.57% YoY to -$66.16 million, and EPS declined by 44.05% YoY to -$0.47. Gross margin remained at 100%. The financials indicate poor growth and profitability.
Multiple analysts downgraded the stock to Neutral or Hold following the acquisition announcement, with price targets aligning closely to the acquisition price of $38. Analysts do not expect another bidder to emerge.
